ClinicalTrials.gg
CompletedNCT02156492Updated Oct 10, 2018Results posted

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

A Phase 1 interventional study of Evacetrapib and Simvastatin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to investigate how the body responds to evacetrapib and to evaluate the safety and the effect of evacetrapib, alone and in combination with selected statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4 weeks and part two will last up to 5 weeks, not including screening. Participants may only enroll in one part.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are native Chinese and living in China.
  • Are overtly healthy males or females as determined by medical history and physical examination.
  • Female participants:

    • Women not of
    • Women of child-bearing potential must correctly use 2 forms of reliable to avoid getting pregnant during the study and for 3 months after the study is completed.
  • : 19.0 to 24.0 kilogram per square meter (kg/m\^2)
  • BP and pulse rate at both supine and standing positions of approximately a systolic BP ≤ 140 millimeter of mercury (mm Hg), and diastolic BP ≤ 90 mm Hg
  • Participants with untreated hypercholesterolemia may be included if not on an herbal or other traditional Chinese medicines (TCM)
  • Have no known liver disease
  • Have given written

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in a clinical trial involving an product (IP) or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have known allergies to evacetrapib, simvastatin, or atorvastatin, related compounds or any components of the formulation
  • Have previously completed or withdrawn from this study or any other study investigating evacetrapib, and have previously received the IP within 3 months.
  • Have a history within the last year or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
  • Show evidence of significant active neuropsychiatric disease.
  • Regularly use known drugs of abuse
  • Are women with a positive pregnancy test or women who are lactating.
  • Have used or intend to use over-the-counter or prescription medications (including vitamins/mineral supplements) or TCM 14 days prior to the first dose and during the study.

    • Hormonal are permitted.
  • Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of organic anion transporting polypeptide 1B1 (OATP1B1), or of any other transporters involved in simvastatin or atorvastatin disposition, or of any drugs or substances that are known to be strong inducers or inhibitors of cytochrome P450 3A () within 30 days prior to the first dose and throughout the study.
  • Donated blood of >400 mL within the last month.
  • Drink alcoholic beverages with intake that exceeds 28 units per week (males) and 21 units per week (females), or are unwilling to stop alcohol consumption 48 hours prior to dosing until discharge from the clinical research unit (CRU) (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
  • Are unwilling to comply with the dietary requirements/restrictions during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Evacetrapib Single

    Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.

    Drug: Evacetrapib

  • Experimental
    Evacetrapib Multiple

    Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.

    Drug: Evacetrapib

  • Active comparator
    Simvastatin

    Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.

    Drug: Simvastatin

  • Experimental
    Evacetrapib and Simvastatin

    Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.

    Drug: Evacetrapib · Drug: Simvastatin

  • Active comparator
    Atorvastatin

    Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.

    Drug: Atorvastatin

  • Experimental
    Evacetrapib and Atorvastatin

    Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.

    Drug: Evacetrapib · Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib

    Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.

    Time frame: Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose

  2. PK: Maximum Concentration (Cmax) of Evacetrapib

    Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.

    Time frame: Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose

  3. PK: Time to Maximum Concentration (Tmax) of Evacetrapib

    Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.

    Time frame: Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose.

  4. PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin

    Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).

    Time frame: Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose

  5. PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin

    Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.

    Time frame: Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose.

  6. PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin

    Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.

    Time frame: Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose.

Secondary outcomes

  1. Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)

    Time frame: Single Dose Day 2 and Multiple Dose Day 22

07

Results

Posted Oct 10, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestoneCohort A: Evacetrapib Single and Multiple DoseCohort B: Evacetrapib and SimvastatinCohort C: Evacetrapib and Atorvastatin
Started162422
Received at least one dose of study drug162422
Completed162322
Not completed010
Withdrew: No reason given010
Period 2
Participant flow — Period 2
MilestoneCohort A: Evacetrapib Single and Multiple DoseCohort B: Evacetrapib and SimvastatinCohort C: Evacetrapib and Atorvastatin
Started162322
Completed162322
Not completed000
Period 3
Participant flow — Period 3
MilestoneCohort A: Evacetrapib Single and Multiple DoseCohort B: Evacetrapib and SimvastatinCohort C: Evacetrapib and Atorvastatin
Started02322
Completed02222
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryPharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib

Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.

Time frame:
Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose
Reported as:
Geometric mean · nanogram * hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib
nanogram * hour per milliliter (ng*h/mL)Evacetrapib Single and Multiple Dose
Day 17700 ± 74
Day 1423600 ± 33
PrimaryPK: Maximum Concentration (Cmax) of Evacetrapib

Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.

Time frame:
Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose
Reported as:
Geometric mean · ng/mL
PK: Maximum Concentration (Cmax) of Evacetrapib
ng/mLEvacetrapib Single and Multiple Dose
Single Dose Day 1418 ± 118
Multiple Dose Day 14954 ± 52
PrimaryPK: Time to Maximum Concentration (Tmax) of Evacetrapib

Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.

Time frame:
Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose.
Reported as:
Median · hours (h)
PK: Time to Maximum Concentration (Tmax) of Evacetrapib
hours (h)Evacetrapib Single and Multiple Dose
Single Dose Day 13.00 (2.00 to 6.00)
Daily Dose Day 143.00 (2.00 to 4.00)
PrimaryPK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin

Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).

Time frame:
Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose
Reported as:
Geometric mean · ng*h/mL
PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin
ng*h/mLEvacetrapib Daily and SimvastatinEvacetrapib Daily and Atorvastatin
Days 5-1410700 ± 3610600 ± 30
Days 15-229640 ± 489480 ± 53
PrimaryPK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin

Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.

Time frame:
Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose.
Reported as:
Geometric mean · ng/mL
PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin
ng/mLEvacetrapib Daily and SimvastatinEvactrapib Daily and Atorvastatin
Days 5-141180 ± 521120 ± 36
Days 15- 221020 ± 681000 ± 73
PrimaryPK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin

Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.

Time frame:
Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose.
Reported as:
Median · h
PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin
hEvacetrapib Daily and SimvastatinEvacetrapib Daily and Atrovastatin
Days 5-143.00 (2.00 to 4.00)3.00 (2.00 to 6.00)
Days 15- 223.00 (2.00 to 4.00)3.00 (2.00 to 4.00)
SecondaryEffect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)
Time frame:
Single Dose Day 2 and Multiple Dose Day 22
Reported as:
Mean · millimoles per liter (mmol/L)
Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)
millimoles per liter (mmol/L)Evacetrapib Single Dose Day 2Evacetrapib Multiple Dose Day 22
HDL-C1.641 ± 0.2112.676 ± 0.373
LDL-C2.289 ± 0.4831.241 ± 0.574
TG0.984 ± 0.3121.221 ± 0.356

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evacetrapib Single Cohort A—0/16 (0%)0/16 (0%)
Evacetrapib Multiple—0/16 (0%)0/16 (0%)
Simvastatin—0/24 (0%)0/24 (0%)
Evacetrapib Single Cohort B—0/23 (0%)0/23 (0%)
Evacetrapib and Simvastatin—0/23 (0%)0/23 (0%)
Atorvastatin—0/22 (0%)0/22 (0%)
Evacetrapib Single Cohort C—0/22 (0%)0/22 (0%)
Evacetrapib and Atorvastatin—0/22 (0%)0/22 (0%)

Baseline characteristics

Participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort ACohort BCohort CTotal
Mean29.1 ± 8.027.5 ± 2.927.9 ± 4.928.02 ± 5.25
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female3025
Male13242057
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
American Indian or Alaska Native0000
Asian16242262
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Cohort ACohort BCohort CTotal
China16242262
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100034, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2014
First posted
Jun 5, 2014
Start
Jun 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Oct 10, 2018
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02156492
Responsible party
Sponsor
First posted
Jun 5, 2014
Start date
Jun 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Oct 10, 2018
Last update
Oct 10, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Evacetrapib · Simvastatin · Atorvastatin

Start the discussion